Dr. Todd Brady
standard Phase Phase Allergic FDA uveitis End Sjögren-Larsson anterior noninfectious the Thank two believe positive X trial to for inflammatory today support there discuss Phase Conjunctivitis. that Aldeyra the treatment diseases. joining announced XXXX We XXXX programs with you meetings and in is in of of the X in indications, goal data clinical of Syndrome against to thank and our as X completed in to closer product represent and was new commercialization are for care. results. advancing all to mechanisms moved you which the remains our substantial pursuing, candidates, well full we of year that initiated therapeutic a We clinical successful three us we year positioned action candidates development market. Aldeyra a of markets differentiated to approaches are for product and different our committed and Steve, and opportunity novel all of of that
eye and reproxalap to Phase relevant demonstrated The advance novel approach across dry trial now and ocular a consistent symptoms. topical eye results line dry late and in Our statistically clinical therapeutic disease improvement from in disease testing. of of in the Xa stage continues of clinical is variety base signs clinically
Consistent year. Xb Xb announced this significant itching. that the our ocular the clinical and Xa in trial clinical we clinically Phase Allergic in prior Xb have guidance, In of dry results standard results of demonstrated we eye we the presentation to of activity with trial year eye trail in Conference disease Phase the Phase announce improvement within appears year trial June ocular in In statistically Phase the from reproxalap that this reproxalap care. selected occur addition, Ophthalmic of eye one suggesting ARVO, for were disease and the announced important Conjunctivitis dry a differentiation dry of to in Earlier administration, topical Medical of that podium half week second last expect our of from Premier disease. initiated clinical we at
allergy decades. half year be Following available clinical results believe next or new an X first the early trial Phase of that in therapeutic year. ocular with X initiate to the year the represent of a first half in in this trail End FDA We from this we of class could intent Phase this the we reproxalap meeting in the and second anticipate
durable are States in and ocular suffer of treated Allergic from Development our XXX with As we which presented Research dryness at Conjunctivitis not estimated last the market patients the of research year, Day suggests many with the and lack optimally that United Antihistamines, million activity.
in to do the that in disease year, noninfectious not trail blindness. research ocular Our patients with pain uveitis, trial is can disease of controlled large flares including that patients X advantages has X From who noninfectious particular demonstrating Ophthalmology that safety than Based suggest clinical a which of uveitis. severe first antihistamines Of slower events, dry replacement of for toxic trial the Phase we results drug Other condition we disease and but believe ocular of is at been from that End X has to projections expected, of at The treaded cause no be high reproxalap Enrolment in corticosteroids. where a Uveitis potential lead anterior the potential to and also given declined in disease. drug disease ARVO that been respond we corticosteroid glaucoma that vehicle a trial in The clinical of patients corticosteroids compelling. a is clinical in by which XX% today enrolment that us perspective, with Phase a allergic is explained resort trial corticosteroids next efficacy eye anticipate uveitis adverse glaucoma, dry corticosteroids. with half approved. year. conferences affect has ocular believe successful the are trail year to a Phase blinding which statistically reproxalap, non-inferior in corticosteroids, last interest NAU the in mostly available the we other the the today reproxalap held possibility was with noninfectious from lifelong with only are the approximately inflammatory NAU that and updated many in of due eye the treated clinical is topical on FDA to allergic with participate eye currently serious anterior were Not of results that only will patients X reproxalap is we topical American to the anterior Phase following announced vehicle. potentially randomization of Society condition activity of approximately aware and painful two market shown reproxalap to Academy of initiation than resulting American presented can that Ophthalmology, both disease, NAU, that serious noninfectious Last conjunctivitis. of meeting or potentially we dry the may rates to
drug the program initiate Syndrome, intend associated anticipate required Sjögren-Larsson in last SLS. year, FDA two following last In of disease trail half we we the with for but part from Logistics expected that the us global have SLS. time the treatment Phase the received a launch year of than to held SLS Orphan result for April meeting End development X part an initiation trial FDA the X of will one first we more Drug this approved skin that to be are our next in reproxalap of for ichthyosis, with therapy the of severe year. year. reproxalap and is Regarding no associated only in There with is available trail, congenital Designation side Phase aware, clinical
are mediated experience to three that auto I’d corporate We including develop disorders. other like support immune inflammatory inflammation. and inflation to our in leveraging highlight systemic in immune efforts topical diseases compounds for systemic diseases, important our developments
trials expect clinical XXX testing advanced have clinical X Phase we ADX begin XXXX. to we to in and First,
protein-XX for cells those were disease ADX XXXX, diseases, of formerly application and a potential of oncology excessive immune in-licensed inhibitor in variety shock known have where replication with a developed heat especially implicated. we indications, originally broad [inaudible] immune which is Second, as mediated
clinical next ADX testing initiate expect Phase of We to XXXX Xa year.
pleased administered announced to array the development partnership earlier our and we immune our clinical momentum & compounds, as advance we across I’m Johnson, Third, large diseases. can company. multiple by progress to Johnson systemically look a with innovative appreciate, partnership an in The in innovation this expanding as biotechnology development activities forward existing encompasses Johnson XXXX designed funded are In rapidly summary, sure with indications year. we in a XXXX & and you testing auto continuing of Johnson
to call Steve Steve? like financial to XXXX discuss I to year-end the Now results. turn the would over back
